More than a decade has passed since the conceptualization of the "alarmin" hypothesis. The alarmin family has been expanding in terms of both number and the concept. 
| INTRODUCTION
Alarmins are endogenous, constitutively expressed, chemotactic, and immune activating proteins/peptides that are released as a result of degranulation, cell injury or death, or in response to immune induction. Alarmins function as intercellular signals defense by interacting with chemotactic and pattern recognition receptors (PRRs) to galvanize immune cells in host defense. 1 Only when alarmins are released in excess by severe injuries and maximal stimulation do they result in the dangerous effects of potentially lethal cytokine storm. They have therefore also been considered damage-associated molecular patterns (DAMPs) 2 and this term has been used interchangeably with alarmins.
In 2001, Polly Matzinger proposed that the immune system is geared to respond to DAMPs that resulted from microbial attack with ensuing cell injury and death. 3 DAMPs were very broadly defined to include both exogenous pathogen-associated molecular patterns (PAMPs) such as bacterial lipopolysaccharide, CpG oligodeoxynucleotide, and flagellin, and deleterious endogenous products of damaged and dead cells. 3 However, we prefer to identify the endogenous alarmins as a subset of endogenous DAMPs that interact with PRRs such as Tolllike receptors (TLRs) as cytokine-like mediators that participate in host defense and are usually not dangerous.
How did we arrive at this alarmin concept? A serendipitous observation initiated this research. In 1995 we performed a rather simplistic experiment to ensure that interleukin-8 (IL-8), an in vitro neutrophil chemoattractant, was also capable of attracting neutrophils in vivo. As expected, we observed that upon subcutaneous injection of IL-8 mice developed an acute inflammatory response characterized by neutrophilic infiltrates at 24 hours. However, we unexpectedly observed that the inflammatory site persisted and, at 72 hours, was infiltrated only by mononuclear cells. We therefore hypothesized that neutrophils produced a chemoattractant for the monocytes/macrophages and predicted it to be a chemokine such as monocyte chemotactic peptide 1 (MCP-1/CCL2). Fortuitously our laboratory was joined at that time for a summer sabbatical by Dr. Oleg Chertov, a Russian biochemist.
We asked him to determine the identity of the neutrophil-derived attractant of mononuclear cells. He informed us several months later that it was a 1500 Dalton moiety. I informed him this was too small to be a chemokine and therefore undoubtedly a contaminant. He countered that he had performed the experiment three times and that the amino acid sequence of this small peptide identified it as a defensin. 4 I
asked him "what is a defensin?" Defensins had initially been identified in 1985 as "antimicrobial peptides" (AMPs) by Robert Lehrer and colleagues. 5 Our data thus indicated they also interacted with inflammatory cells of the host and we reported our findings that these defensins mobilized cells engaged in host defense in several papers 4, 6, 7 that were largely ignored until Dr. De Yang joined our laboratory and found out
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that human β defensins interacted with the chemokine-receptor CCR6
to induce the migration of immature dendritic cells (DCs). 8 This observation upset the chemokine research community because it "contaminated" their complicated network of chemokine-receptor interactions even more. It also upset the microbiologists who were studying the natural antibiotic activities of AMPs and were afraid to be outnumbered by immunologists preempting their studies on AMPs. Suffice it to state that neither discipline has suffered any interference or decline in their activities based on these observations.
The discovery of defensins' chemotactic activity was followed by the identification of the DC-activating property of β defensins. 9, 10 Subsequently, other granule-derived AMPs as well as the now famous high-mobility group box-1 (HMGB1) were shown to have both chemoattracting and activating effects on leukocytes including DCs and hence the capacity to induce innate and adaptive immune responses. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] This led us in 2004 to propose considering these endogenous moieties that can chemotactically mobilize and are also able to activate the immune system as endogenous alarmins. 1, 27 As alarmins are all constitutively expressed and rapidly released in response to infection and non-programmed cell death, they are available as "first responders" and by recruiting and activating leukocytes including DCs, alarmins can initiate both innate/inflammatory and adaptive immune responses. [28] [29] [30] [31] [32] [33] [34] Since then a plethora of additional host-derived molecules have been called alarmins. The definition of alarmins has been broadened to include endogenous moieties generated as a result of non-programmed cell death with the capacity to induce innate/inflammatory and adaptive immune responses. 31, 32, [35] [36] [37] [38] Currently, alarmins include a surprising number of chromatin-binding moieties in addition to HMGB1, such as HMGN1, IL-1α, and IL-33, as well as heat shock proteins (HSPs), S100 proteins, ATP, and uric acid crystals, which can be classified based on their origin (Table 1) .
There are probably a number of alarmins that remain to be identi- 
| CONTRIBUTION OF ALARMINS TO INNATE IMMUNE RESPONSES

| Alarmins activate leukocytes
| Alarmins participate in the activation of inflammasomes
While most alarmins promote the expression and production of in- 
| Alarmins indirectly promote the recruitment of leukocytes
Activation of various leukocytes by alarmins results in the production of many chemokines, such as CXCL5, CXCL7, CXCL8, CXCL9, CXCL10, CXCL12, CCL2, CCL3, CCL5, CCL7, CCL8, and CCL20, which are well-established contributors to the recruitment of leukocytes during the development of innate immune responses. 117, 118, 123 In addition, some alarmins also upregulate the expression of adhesion molecules by endothelial cells and leukocytes, for example, HMGB1
increases endothelial expression of ICAM-1, β1 and β2 integrins. 124 Human β defensing 2 has been shown to induce the arrest of Th17 cells on inflamed endothelial cells in an ICAM-1-dependent manner. 125 In addition, S100A8/A9 reduces neutrophil rolling and increase leukocyte adhesion by activating β2 integrin. 126 Many alarmins, such as defensins, cathelicidins, EDN, granulysin, and HMGB1, possess direct antimicrobial activities 26, 27, 128, 129 and therefore also contribute to eliminating pathogens and shaping the host's microbiota that, in turn, regulates immune responses and influence infection and inflammatory disorders. One example is cathelicidin. In patients with atopic dermatitis, a common Th-2 type inflammatory skin disorder, the lack of cathelicidin/LL-37 production due to suppression by high levels of IL-4 and IL-13 results in greatly reduced defense against vaccinia virus infection. 130 Furthermore, it has recently been found that mouse cathelicidin/CRAMP is produced by pancreatic β-cells in response to certain short-chain fatty acids generated by gut microbiota, which modulates the pancreatic inflammation associated with diabetes. Non-obese diabetic (NOD) mice, due to deficiency in those short-chain fatty acids, are defective in CRAMP production 131 and CRAMP administration to NOD mice dampens the development of autoimmune diabetes in NOD mice. 131 Thus, alarmins in addition to networking with other endogenous host defense molecules also interact with exogenous agents influencing our host defense. 
| ALARMIN-SENSING RECEPTORS AND SIGNAL TRANSDUCTION PATHWAYS
| Signal transduction pathways for alarmininduced leukocyte activation
Alarmins trigger PRRs, such as TLRs, receptor for glycation endproducts (RAGE), P2X7, and NLRP3, and members of the IL-1R family including IL-1R1 and ST2 for the activation of various leukocytes ( Figure 1 ). IL-1α and IL-33 act on IL-1R1 and ST2, respectively. 30, 45, 46 Defensins stimulate TLR4 on conventional DCs or TLR7/8/9 in plasmacytoid DCs for the induction of TNFα, IL-6, and IFN production via the activation of transcriptional factors NF-κB, IRF3, and IRF7. 10, 72, 75 Cathelicidin activates neutrophils, macrophages, DCs, and fibroblasts using TLR7,8, 9 77, 78, 134 or P2X7 55, 136, 137 for the induction of inflammatory mediators like TNFα, IFNα, COX2, and PGE2. EDN activates conventional DCs through triggering TLR2 and consequently the activation of NF-κB and multiple MAPKs, leading to the production of inflammatory cytokines such as TNFα, IL-6, and IL-8. 24, 79 Many alarmins act on TLR4 to induce the production of various inflammatory mediators by macrophages or DCs, including β defensins, 10 HSPs, 62, 88, 89, 138 HMGN1, 82 granulysin, 119 S100 A8/A9, 66, 126, 139 and HMGB1. 132, 133 Signal transduction through IL-1R1, ST2, and TLR2, TLR3, TLR4, TLR7, TLR8, TLR9, and RAGE relies on distinct adapter proteins including MyD88, TRIF, TIRAP, and TRAM. 30, 140, 141 Despite the complexity of receptor usage and distinct receptor-proximal signaling effect, alarmins triggering TLRs, IL-1R1/ST2, and RAGE converge in the activation of transcriptional factors such as NF-κB, IRFs, and AP-1, etc., which are responsible for promoting the transcriptional expression of mediators including many chemokines and cytokines ( Figure 1 ).
While most chemokines and cytokines are bioactive after translation and secretion, IL-1β and IL-18 are produced in macrophages and DCs as pro-forms that require cleavage by caspase 1 whose activation depends predominantly on the activation of NLRP3 inflammasome. 30 The induction of the pro-forms of IL-1β and IL-18 can be promoted by many mediators including alarmins/DAMPs, PAMPs, and cytokines. 29, 30, 33, 67, 70, 95, 142 The activation of NLRP3 inflammasome requires two steps: upregulation of production and assembly.
30,95,143
The first step is mediated primarily by TLR adapter MyD88-or cytokine-driven activation of NF-κB, which promotes the production of NLRP3. 95, 143, 144 Many alarmins can potentially contribute to this step, some of which has recently been confirmed. 97 The second step involves the assembly of NLRP3, ASC, and pro-caspase 1 into a complex and autocatalytic cleavage of pro-caspase 1 into active caspase 1, which in turn catalyzes IL-1β and IL-18 processing. 30, 95, 143 Several alarmins are shown to promote this step. ATP via P2X7 causes K + efflux to promote NLRP3 inflammasome assembly and activation 95, 98, 145 and so do α defensing and cathelicidin. 52, 55, 136, 137 Uric acid crystals or even soluble uric acid upon entering into macrophages causes lysosomal rupture to release proteases such as cathepsin B, which promote the activation of NLRP3 inflammasome and hence the production of active IL-1β and IL-18. 95, 96, 146, 147 Thus, it has been determined that alarmins can provide the necessary signals for the activation of NLRP3 inflammasome (Figure 1 ).
| Signal transduction pathways for alarmininduced leukocyte migration
Leukocyte migration induced by most alarmins can be inhibited by pretreatment of the target cells with pertussis toxin, a bacterial toxin capable of preventing G proteins from interacting with GiPCRs on the cell membrane by catalyzing the ADP ribosylation of the α i subunits of the heterotrimeric G protein. 8, 11, 12, 20, 63, 81, 100, 103, 104, 148 This indicates that the direct chemotactic effects of many alarmins are mediated by GiPCRs ( Figure 1 ). β-defensins use CCR6 8, 9, 122, 149, 150 and CCR2 151, 152 to induce the migration of DCs and monocytes/macrophages. Human and mouse cathelicidins induce the migration of leukocytes via FPRL1 or its mouse ortholog FPR2, 12, 104 however, human cathelicidin/LL-37
induces MC migration and degranulation through MrgX2, a GiPCR belonging to Mas-related gene family. 44 Recently, LL-37 has also been reported to induce neutrophil migration via CXCR2. 153 ATP uses several 116 Receptors other than GiPCRs also participate in alarmin-induced leukocyte migration. HMGB1-induced migration of neutrophils, monocytes, and DCs is dependent on the presence of RAGE. 45, 81, 110, 111, 154 While S100A8-and S100A15-induced migration of neutrophils and macrophages is mediated by GiPCRs, 108,109 monocyte migration induced by S100A7 is RAGE -dependent. 108 IL-33-induced cell migration is mediated by ST2. 112, 114 As many receptors mediating the chemotactic effects of alarmins are GiPCRs (e.g. FPRL1, CCR2, CCR6, etc.) whose signaling pathways have been elucidated in some details, 32, 117, 155, 156 it is likely that alarmins trigger similar intracellular signaling pathways to those of chemoat- and promotes OVA-specific humoral and cell-mediated immune responses. 104 In addition, co-administration of OVA and HMGB1, 80 EDN, 79 and HMGN1 Given the prominent roles of alarmins in innate/inflammatory and adaptive immune responses, the availability, activity, and signaling of alarmins must be intricately regulated. The best studied example is HMGB1. First, the activities of HMGB1 is regulated by redox states.
The reduced form is chemotactic, 120 however, breakage of the intramolecular disulfide bond between Cys 23 and Cys 45 or oxidation of the free thiol group of Cys 106 to sulfonate destroys its cell-activating activity. 57, 120, 178 It should be mentioned that HMGN1, in contrast,
should not be subject to such redox regulation because it lacks Cys residue. Consequently, HMGN1 is not inactivated at inflammatory sites. Second, HMGB1 can bind to CD24, which, through mobilizing Siglec-10 (Siglec-G in mice), counters HMGB1-induced DC activation through TLR4. 179 Third, the N-terminal domain of thrombomodulin can bind to HMGB1 and thrombin to facilitate thrombin-mediated degradation of HMGB1. 180, 181 Finally, T-cell immunoglobulin domain and mucin domain 3 (TIM-3), a checkpoint inhibitor expressed on DCs in tumors, has been shown to bind HMGB1, which functions to prevent HMGB1 from interacting with nucleic acids and hence inhibiting the efficacy of anti-tumor DNA vaccines or chemotherapy. 182 The detailed mechanisms that negatively regulate the availability/activity of other alarmins remain largely undetermined.
| ALARMINS AND TUMOR IMMUNITY
Tumor formation is accompanied by leukocyte infiltration and innate/ inflammatory responses, which leads to either induction of anti-tumor immunity or promotion of tumor progression and metastasis by fostering tumor growth and concomitant immunosuppression. 183 Given their diverse effects on leukocytes and immune system, alarmins can be envisaged to play complex roles in cancer immunity (Table 2 ).
| HMGN1
HMGN1 preferentially induces Th1-polarized immune responses 82 and has recently been shown to promote the development of protective anti-tumor immunity. 184, 185 EG7 mouse thymoma expressing OVA as a surrogate tumor-associated antigen (TAA) was found to grow much faster in HMGN1-deficient mice than littermate-matched controls. 185 In addition, HMGN1 −/− mice exhibited a higher incidence of spontaneous formation of multiple malignant tumors than their HMGN1 +/+ littermates. 186 Furthermore, EG7-bearing HMGN1 −/− mice generated fewer OVA-specific CTLs than EG7-bearing HMGN1 +/+ mice, suggesting that HMGN1 contributed to the generation of tumor-specific CTL response and anti-tumor immune protection, a conclusion supported by the fact that HMGN1-expressing EG7 tumors grew more slowly than control EG7 tumors. HMGN1-stimulated protective antitumor immunity relied on T cells because it was abolished by depletion of CD4 + and CD8 + T cells. Mice DNA vaccinated with a construct directing the expression of HMGN1-gp100 fusion protein indeed induced gp100-specific immune responses and resistant to challenge with mouse B16 melanoma, providing additional support for the crucial role of HMGN1 in the generation of anti-tumor immunity. 
| HMGB1
HMGB1 can also promote Th1-polarized immune response and has been implicated in anti-tumor immune responses. 80, 187, 188 HMGB1 enables the TLR4-dependent activation of DCs, which promotes antigen cross-presentation to CTLs favoring the development of anti-cancer immune responses in mouse tumor models and human patients. 189 In addition, injection of a monoclonal neutralizing antibody specific for HMGB1 abolishes the immunogenicity of anthracycline-treated CT26 or EG7 cells in vivo. 190 However, recent studies suggest that HMGB1
can also promote tumor progression, metastasis, and formation of immunosuppressive tumor microenvironment by promoting inflammation 191, 192 or interacting with TIM-3. 182 Thus, HMGB1 acts as both a tumor suppressor and an oncogenic factor in tumorigenesis and cancer therapy depending on the context and the study conditions, as well as HMGB1 location and modification as recently reviewed. 
| Defensins
Human α defensins was shown a long time ago to enhance the antibody response as well as immunoprotection to a syngeneic mouse B-cell lymphoma, providing perhaps the earliest hint that alarmin can promote anti-tumor immune responses. 7 Upon delivery by DNA vaccination in the form of defensin-TAA fusion, β defensin 2 and 3 promote anti-tumor immunity toward multiple mouse B-cell lymphomas, in part, through targeting and activating DCs. 9, 10 In addition, mice inoculated with a syngeneic leukemia engineered to express mouse β-defensin 2 induces the generation of protective anti-tumor immunity dependent on NK and CD8 T cells. 167 Therefore, defensins, at least the ones tested, have the capacity to induce the generation of protective anti-tumor immune responses. However, it has gradually been shown that a number of human cancers of squamous keratinocytes (e.g. cervical, esophageal, salivary gland, head and neck carcinoma, colon, etc) show elevated expression of β-defensin 2 and/or 3. [194] [195] [196] [197] [198] [199] Both β-defensin 2 and 3 promotes tumor cell proliferation and/or invasion. 194, 197, 198 β-defensin 3 upregulation can be triggered by either epidermal growth factor or human papillomavirus 199 and its promotion of tumor cell proliferation involves the activation of NF-κB. 198 In contrast, human β-defensin 1 has been shown to inhibit the proliferation of several types of cancer cells. 200, 201 There are six α defensins and more than 30 β-defensins in humans, 202 and their contributions to tumor immunity require further investigation.
IL-1α
IL-1α, upon synthesis, translocates to the nucleus to function as a transcriptional factor to regulate gene expression. 30, 70, 142 IL-1α is known to inhibit the proliferation of many cancer cells via regulating metabolism, cell cycle, and inducing apoptosis. 30, 70, [203] [204] [205] Overexpression of IL-1α on the surface of fibrosarcoma or lymphoma cells promotes 
| HSPs
Induction of anti-tumor CTL responses requires TAAs to be transferred to DCs for cross-presentation. 220 HSPs such as HSP70, HSP90, gp96, and calreticulin are critical for TAA cross-presentation using CD91 as the receptor. [220] [221] [222] [223] In addition, purified HSPs stimulate DC maturation [86] [87] [88] [89] [90] and generation of Th1-polarized anti-tumor immunity. 88, 90, 220, 224 Furthermore, it has recently been shown that exogenous HSP70 triggers the secretion of endogenous HSP70 to tumor cell surface, which sensitizes cancer cells for CTL-mediated killing. 
| ATP
ATP induces DC maturation 91, 92 and inflammasome activation 94, 95, 98 and consequently promotes the generation of anti-tumor immunity. 94 This is supported by a recent report showing that knockout of P2X7 in mice, the major receptor mediating the effect of ATP on the activa- 234, 235 Together with its DC-activating activity, S100A8/A9 may play a role in tumor immunity. However, S100A8/A9 promotes tumor growth by inhibit the differentiation of DCs and macrophages and enhance MDSC production, recruitment, and infiltration. 236, 237 S100A9-deficient (also lacking S100A8 expression) mice generates potent anti-tumor immune responses to reject implanted tumors. Given the critical roles of NK, CTL, and IFNγ in protective immunity against cancers, Th1-polarizing alarmins (e.g. HMGB1, HMGN1, and HSPs, etc) are potentially good candidates to be used for designing immunotherapies for cancers. Based on the critical roles of HMGN1 in the development of protective anti-tumor immunity, 184, 185 we further investigated whether HMGN1 could be harnessed for the treatment of growing tumors in a therapeutic vaccination approach.
We have developed a therapeutic "cocktail" (termed "TheraVac") con- 
| CONCLUSIONS AND PERSPECTIVES
Alarmins are multifunctional endogenous molecules that are sensed by host immune system and contribute to host defense. As they are constitutively available they are first reactors to infectious and trau- with the capacity to modulate alarmins and potential therapeutic applicability.
